Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas Medicine Announces First Quarter 2026 Results and Business Updates
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of “Moderate Buy” from Analysts
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts
Is Editas Medicine Going to $0?
Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
Editas Medicine to Participate in Upcoming Investor Conferences
Genflow Biosciences PLC Announces Directorate Change
Top 3 Genomics Stocks to Consider for Your Portfolio
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Why Is Editas (EDIT) Down 16.9% Since Last Earnings Report?
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol
Editas Medicine, Inc. - Special Call
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Why Editas Medicine Stock Was Skyrocketing This Week
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
Can This Beaten-Down Stock Bounce Back?
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
2 Beaten-Down Stocks to Avoid
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Why Is Editas (EDIT) Up 40% Since Last Earnings Report?
1 Stock Down 97% That Could Double, According to Wall Street
I Missed The Quantum Rally - I Won't Miss The Next One
Editas Medicine: A Cautionary Tale for Investors
Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June